Angina News and Research

RSS

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.

New discovery holds promise for TB treatment

New findings on how tuberculosis bacteria develop multi-drug tolerance point to ways TB infections might be cured more quickly.

4 Mar 2011

Miracor completes PICSO System pilot study in patients with ACS

Miracor Medical Systems GmbH announced today the successful completion of the pilot study of its PICSO System, designed to improve acute coronary syndrome revascularization following primary percutaneous coronary intervention.

4 Mar 2011

Shire receives European Commission approval for self-administration of FIRAZYR for HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the European Commission has approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. FIRAZYR is the first and only treatment for acute Type I and Type II hereditary angioedema (HAE) attacks licensed for self-administration in Europe.

4 Mar 2011

Dizziness, nausea and achiness are symptoms of heart attack in females

Dizziness, nausea and achiness – no, these are not symptoms of the flu but signs of a heart attack in females. While heart attacks affect both men and women, the symptoms of a heart attack are surprisingly different between the genders. Virginia Health Information (VHI) this week released its Cardiac Care Report which provides consumers information comparing heart healthcare in Virginia. This year's report reveals women undergoing open heart surgery continued a five year trend of higher than expected readmission rates.

25 Feb 2011

$MHI begins patient enrollment for new device to treat refractory angina$

MHI begins patient enrollment for new device to treat refractory angina

The interventional cardiology team at the Montreal Heart Institute recently began patient enrolment for a new device, the Neovasc Reducer, designed to treat patients suffering from refractory angina.

25 Feb 2011

Nitroglycerin ointment may help in improving older women’s bone health: Study

A new study has shown that nitroglycerin ointment, that is used for chest pain or angina can be beneficial in postmenopausal women in improving their bone density. In this group of women, the bone becomes increasingly weak and brittle and leads to easy fractures. The study showed that postmenopausal women who used it for 2 years showed a modest increase in bone mineral density and decrease in bone resorption (loss). The study was published in the February 23 issue of JAMA.

22 Feb 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the second quarter of Fiscal Year 2011.

14 Feb 2011

ECR launches sleep aid product, Zolpimist Oral Spray in the US

NovaDel Pharma Inc. today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc.. ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

Consumer Reports Health unveils ratings of nine common screenings for heart disease

Consumer Reports Health unveils Ratings of nine common screenings for heart disease based on systematic review of evidence; some screenings work well while others deemed not worth the risk for healthy individuals

3 Feb 2011

Malarial drugs may help treat specific form of frontotemporal dementia

Frontotemporal dementia is caused by a breakdown of nerve cells in the frontal and temporal region of the brain, which leads to, among other symptoms, a change in personality and behavior. The cause of some forms of frontotemporal dementia is a genetically determined reduction of a hormone-like growth factor, progranulin.

3 Feb 2011

Mother’s stroke history can help predict daughter’s risk of heart attack

If you're a woman and your mother had a stroke, you may have a risk of heart attack in addition to a higher risk of stroke, according to new research on family history and heart disease published in the American Heart Association journal Circulation: Cardiovascular Genetics.

2 Feb 2011

Employees with heart attack, ACS are major source of health costs

Employees with myocardial infarction and other types of acute coronary syndrome are a major source of direct and indirect health costs, reports a study in the January Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.

21 Jan 2011

PROSPECT trial results shed new light on plaque types that cause unexpected heart attacks

Results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur.

21 Jan 2011

Grayscale IVUS and VH IVUS tissue characterization software help accurate assessment of blockage risk

Volcano Corporation today announced the publication of results from the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study in The New England Journal of Medicine showing that grayscale intravascular ultrasound (IVUS) and Volcano's proprietary VH® IVUS tissue characterization software enable physicians to more accurately assess the risk of individual blockages than the use of the current standard-of-care-- angiographic imaging-- alone.

20 Jan 2011

Higher fruit and vegetable intake lowers risk of dying from ischaemic heart disease

A European study investigating the links between diet and disease has found that people who consume more fruit and vegetables have a lower risk of dying from ischaemic heart disease - the most common form of heart disease and one of the leading causes of death in Europe.

19 Jan 2011

Vasomedical second quarter total revenues increase 353% to $3.801 million

Vasomedical, Inc., a global provider of medical devices, today announced financial results of the three months ended November 30, 2010. Vasomedical is a world leader in the noninvasive treatment of cardiovascular diseases.

18 Jan 2011

'Pacemaker' Hcn4 gene responsible for generation of repetitive activity in SAN tissue and heart rate regulation

The study of Dario DiFrancesco and his equipe identifies the "pacemaker" Hcn4 gene as the gene functionally responsible for the generation of repetitive activity in sinoatrial node tissue and for the regulation of heart rate. Hcn4 codes for HCN4 channels, the molecular components of "funny" ion channels of pacemaker cells of the sinoatrial node (SAN) tissue.

14 Jan 2011

Investigators find reduction in STEMI rates, but slight increase in NSTEMI incidence rates

Coronary syndromes vary in severity, ranging from unstable angina, non-ST segment elevation myocardial infarction, to ST-segment elevation myocardial infarction, the most severe diagnosis. Little data exist about changing trends in acute myocardial infarction and whether death rates are increasing or decreasing.

13 Jan 2011

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

NovaDel Pharma Inc. today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC, an affiliate of Akrimax Pharmaceuticals.

7 Jan 2011

Angina News and Research

Further Reading

New discovery holds promise for TB treatment

Miracor completes PICSO System pilot study in patients with ACS

Shire receives European Commission approval for self-administration of FIRAZYR for HAE

Dizziness, nausea and achiness are symptoms of heart attack in females

MHI begins patient enrollment for new device to treat refractory angina

Nitroglycerin ointment may help in improving older women’s bone health: Study

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

ECR launches sleep aid product, Zolpimist Oral Spray in the US

Consumer Reports Health unveils ratings of nine common screenings for heart disease

Malarial drugs may help treat specific form of frontotemporal dementia

Mother’s stroke history can help predict daughter’s risk of heart attack

Employees with heart attack, ACS are major source of health costs

PROSPECT trial results shed new light on plaque types that cause unexpected heart attacks

Grayscale IVUS and VH IVUS tissue characterization software help accurate assessment of blockage risk

Higher fruit and vegetable intake lowers risk of dying from ischaemic heart disease

Vasomedical second quarter total revenues increase 353% to $3.801 million

'Pacemaker' Hcn4 gene responsible for generation of repetitive activity in SAN tissue and heart rate regulation

Investigators find reduction in STEMI rates, but slight increase in NSTEMI incidence rates

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News